Perspective Therapeutics (NYSEAMERICAN:CATX) Given Outperform Rating at Wedbush

by · The Markets Daily

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report)‘s stock had its “outperform” rating restated by analysts at Wedbush in a research report issued on Tuesday, Benzinga reports. They currently have a $11.00 target price on the stock. Wedbush’s price target suggests a potential upside of 297.69% from the stock’s current price.

Several other analysts have also recently issued reports on the company. Piper Sandler decreased their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. BMO Capital Markets set a $11.00 target price on shares of Perspective Therapeutics and gave the company an “outperform” rating in a report on Tuesday, August 18th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Finally, Bank of America lowered their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $11.50.

Get Our Latest Research Report on Perspective Therapeutics

Perspective Therapeutics Trading Down 5.3%

CATX opened at $2.77 on Tuesday. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16. The company has a 50 day simple moving average of $3.08 and a two-hundred day simple moving average of $3.71.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. On average, equities research analysts expect that Perspective Therapeutics will post -0.98 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CATX. AXQ Capital LP boosted its position in Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares in the last quarter. Abel Hall LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter valued at about $49,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at about $84,000. Wealth Effects LLC boosted its holdings in shares of Perspective Therapeutics by 32.0% in the 1st quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock valued at $138,000 after buying an additional 8,000 shares in the last quarter. Finally, Taylor & Morgan Wealth Management LLC grew its position in shares of Perspective Therapeutics by 127.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after buying an additional 37,000 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals.

Further Reading